Immunocore
IMCR
58 hedge funds and large institutions have $591M invested in Immunocore in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 8 closing their positions.
8,727% more call options, than puts
Call options by funds: $971K | Put options by funds: $11K
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
18% more funds holding
Funds holding: 49 → 58 (+9)
3.86% more ownership
Funds ownership: 41.23% → 45.09% (+3.9%)
8% less capital invested
Capital invested by funds: $642M → $591M (-$51.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$15.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$9.96M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$9.73M |
| 4 |
SC
Samlyn Capital
New York
|
+$9.61M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$9.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.5M |
| 2 |
PA
Perceptive Advisors
New York
|
-$12.3M |
| 3 |
BCPEMI
Bain Capital Public Equity Management II
Boston,
Massachusetts
|
-$9.95M |
| 4 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$9.51M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.81M |
IMCR Hedge Fund Activity: Q1 2022 in Review
58 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q1 2022, worth a combined $591M — down 8% from $642M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new IMCR positions and 8 closed out — a net gain of 9 holders — while 19 added to existing stakes and 8 trimmed.
The largest buyer was RTW Investments, adding an estimated $15.5M. The largest seller was Fidelity Investments, cutting an estimated $12.5M.
- 58 institutional investors held Immunocore (IMCR) as of Q1 2022, up from 49 in Q4 2021.
- Funds reported $591M of Immunocore stock for Q1 2022, down 8% quarter-over-quarter.
- 17 funds opened new Immunocore positions in Q1 2022 and 8 closed out, a net change of +9 holders.
- The largest Immunocore buyer in Q1 2022 was RTW Investments, an estimated $15.5M added.
- The largest Immunocore seller in Q1 2022 was Fidelity Investments, an estimated $12.5M sold.
Based on aggregated 13F filings for Q1 2022.